"Neuroleptic malignant syndrome" (NMS) derives from the French "syndrome malin des neuroleptiques" and was first described in 1960 by Delay [1] and colleagues in association with haloperidol.
Yet, clinicians treating persons with autism continue to prescribe older neuroleptic agents targeting ... of tardive dyskinesia and neuroleptic malignant syndrome. This article presents a model ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback